NATIONWIDE RESEARCH

HCRN Clinical Trials

Hoosier Cancer Research Network is committed to improving the lives of cancer patients through clinical research. Study participants allow researchers to conduct studies that will improve outcomes for future generations of cancer patients.

View Trials

250+

Clinical trials

100+

Research sites

10k+

Subjects

Our Network

HCRN brings together researchers from across the United States to conduct collaborative investigator-initiated studies that address critical research questions across all cancer types.

Explore our IMPACT

HCRN Directory

HCRN clinical trials are offered through our network of more than 100 academic and community sites throughout the United States. More than 500 researchers across cancer types participate in HCRN’s Clinical Trial Working Groups.

Clinical Trials

Publications

Filter Trials

Filter—Clinical Trials: Status

Currently Enrolling (0)

Enrollment Closed (0)

Study Completed (0)

Cancer Type(s)

Filter—Clinical Trials: Cancer types

Anal (0)

Basket (0)

Bladder (0)

Breast (0)

Breast Cancer (0)

Cancer Type (0)

Carcinoma of Unknown Primary (0)

Cervical (0)

Cholangiocarcinoma (0)

Colorectal (0)

Endometrial (0)

Esophageal (0)

Esophageal/Gastric (0)

Gastric (0)

Gastroesophageal Junction (0)

Germ Cell (0)

Germ Cell Tumors (0)

Gynecologic (0)

Head and Neck (0)

Hepatocellular (0)

Kidney (0)

Leukemia (0)

Liver and Bile Duct (0)

Lung (0)

Lymphoma (0)

Melanoma (0)

Merkel Cell Carcinoma (0)

Mesothelioma (0)

Multiple Myeloma (0)

Mutiple Myeloma (0)

Myelodysplastic Syndromes (0)

Neuroendocrine Tumors (0)

Ovarian (0)

Pancreatic (0)

Prostate (0)

Quality of Life (0)

Quality of Life/Cancer Control (0)

Rectal (0)

Sample Collection (0)

Sarcoma (0)

Small Bowel (0)

Trial Management (0)

Urothelial Carcinoma (0)

Sort by:

Currently Enrolling

HCRN-GU22-595

EXACT: Randomized phase II trial of XL092 in combination with immunotherapy in patients who progress on Adjuvant therapy in Clear Cell RCC

Karie Runcie

Cancer areas:Kidney

Columbia University Irving Medical Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-GI23-617

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

Tiago Biachi de Castria

Cancer areas:Small Bowel

Moffitt Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-GU22-598

Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder

Cancer areas:Bladder

Icahn School of Medicine at Mount Sinai

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-GU23-626

Hispanic/Latino and non-Hispanic BlAck patients treated with niRaparib and abiraterone acetate plus prednisone for Metastatic hOrmone sensitive prostate cancer with deleterious homologous recombinatioN repair alterations: a phase II, open label studY (HARMONY)

Cancer areas:Prostate

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-GU21-551

ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Cancer areas:Bladder

Icahn School of Medicine at Mount Sinai

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-AML20-472

TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents

Cancer areas:Leukemia

AdventHealth Orlando

Rhode Island Hospital

University of North Carolina Lineberger Comprehensive Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-BRE17-141

An Open Label, Phase II Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER2-Positive Breast Cancers

Ruth O’Regan

Cancer areas:Breast

Penn State Cancer Institute

University of Illinois Cancer Center

University of Rochester Medical Center - Wilmot Cancer Institute

University of Wisconsin Carbone Cancer Center

Learn More

See clinicaltrials.gov

Enrollment Closed

HCRN-BRE18-360

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

Cancer areas:Breast

Cleveland Clinic Cancer Center

Duke Cancer Institute

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Memorial Breast Cancer Center at Memorial Regional Hospital

Memorial Sloan Kettering Cancer Center

University of North Carolina Lineberger Comprehensive Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-BRE20-468

A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)

Cancer areas:Breast

Fred & Pamela Buffett Cancer Center

New York University Cancer Institute

Orlando Health Cancer Institute

Parkview Research Center

Penn State Cancer Institute

Providence Cancer Institute

Rutgers Cancer Institute of New Jersey

The Ohio State University

Tufts Medical Center

University of Alabama at Birmingham Comprehensive Cancer Center

University of Arizona Cancer Center

University of Illinois Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Michigan Health-West

University of Michigan Rogel Cancer Center

University of Virginia Cancer Center

University of Wisconsin Carbone Cancer Center

Virginia Commonwealth University

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-BRE21-516

BRIDGET: Secondary BRain metastases prevention after Isolated intracranial progression on Trastuzumab/Pertuzumab or T-DM1 in patients with aDvanced human epidermal Growth factor receptor 2+ brEast cancer with the addition of Tucatinib

Cancer areas:Breast

Dana-Farber Cancer Institute

Duke Cancer Institute

MD Anderson Cancer Center

Novant Health Oncology Specialists

Providence Cancer Institute

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

The Ohio State University

UC San Francisco

University of Michigan Rogel Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-BSK22-562

Observational basket trial to predict response to immune checkpoint inhibitors across solid tumors using a live tumor diagnostic platform (CYBRID-02)

Cancer areas:Basket

AdventHealth Orlando

CARTI

Cleveland Clinic Cancer Center

John Theurer Cancer Center at Hackensack Meridian Health

Meritus Center for Clinical Research / John R. Marsh Cancer Center

Salinas Valley Health

University of Louisville / James Graham Brown Cancer Center

University of North Carolina Lineberger Comprehensive Cancer Center

University of South Florida

University of Wisconsin Carbone Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-GI18-333

Phase 2 study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and gastroesophageaL junction (GEJ) adenocarcinoma (SEQUEL)

Harry H. Yoon

Cancer areas:Gastric Gastroesophageal Junction

Froedtert & the Medical College of Wisconsin

Mayo Clinic

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-GI23-643

Randomized Trial of Regorafenib in Combination with Pembrolizumab or Pembrolizumab Monotherapy for Patients with MSI-H Colorectal Cancer

Cancer areas:Colorectal

AdventHealth Orlando

UPMC Hillman Cancer Center

Learn More

See clinicaltrials.gov

Study Completed

HCRN-GI21-499

A Phase Ib/II Study of Sotorasib Combined with Chemotherapy for Second Line Treatment of KRAS p. G12C Mutated Advanced Pancreatic Cancer

Cancer areas:Pancreatic

No data was found

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-GU16-243

PhAse I/II StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER – (ADAPT-BLADDER) HCRN GU16-243

Noah M. Hahn

Cancer areas:Bladder Urothelial Carcinoma

Columbia University Irving Medical Center

Fox Chase Cancer Center

Fred & Pamela Buffett Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

University of Iowa Holden Comprehensive Cancer Center

Learn More

See clinicaltrials.gov

Enrollment Closed

HCRN-GU18-343

A Phase 2 Study of CAbozantinib in Combination With AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)

Deepak Kilari

Cancer areas:Bladder

Froedtert & the Medical College of Wisconsin

John Theurer Cancer Center at Hackensack Meridian Health

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

University of Rochester Medical Center - Wilmot Cancer Institute

Vanderbilt-Ingram Cancer Center

Virginia Commonwealth University

Learn More

See clinicaltrials.gov

Enrollment Closed

HCRN-GU19-385

Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)

Ulka Vaishampayan

Cancer areas:Prostate

City of Hope

Froedtert & the Medical College of Wisconsin

Knight Cancer Institute at Oregon Health & Science University

University of Michigan Rogel Cancer Center

Winship Cancer Institute of Emory University

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-GU20-436

NePtune: A Phase 2 Study of Neoadjuvant PARP Inhibition followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations

Cancer areas:Prostate

Columbia University Irving Medical Center

Memorial Sloan Kettering Cancer Center

Moores Cancer Center at UC San Diego Health

Penn Medicine Abramson Cancer Center

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Learn More

See clinicaltrials.gov

Enrollment Closed

HCRN-GU20-444

Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer with Selective Bladder Sparing

Matthew D. Galsky

Cancer areas:Bladder

City of Hope

Icahn School of Medicine at Mount Sinai

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

University of New Mexico Comprehensive Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-GU21-517

A Phase 2 Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer (CANOPY)

Cancer areas:Prostate

Moores Cancer Center at UC San Diego Health

The University of Chicago Medicine Comprehensive Cancer Center

University of Wisconsin Carbone Cancer Center

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-GU22-587

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)

Cancer areas:Kidney

Beth Israel Deaconess Medical Center

Columbia University Irving Medical Center

Dana-Farber Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

John Theurer Cancer Center at Hackensack Meridian Health

Moores Cancer Center at UC San Diego Health

Penn Medicine Abramson Cancer Center

The Ohio State University

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Weill Cornell Medicine

Winship Cancer Institute of Emory University

Yale Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-HN23-623

A Phase II, Single Arm, Open Label, Multi-center Trial of Neoadjuvant Radiation and Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Previously Untreated Locally Advanced, Resectable, HPV Mediated Oropharynx Cancer

Cancer areas:Head and Neck

Knight Cancer Institute at Oregon Health & Science University

Moores Cancer Center at UC San Diego Health

Providence Cancer Institute

Learn More

See clinicaltrials.gov

Study Completed

HCRN-LUN17-302

A Phase II Study Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination with Carboplatin in Extensive Stage Small Cell Lung Cancer. HCRN: LUN17-302

Shadia I. Jalal

Cancer areas:Lung

No data was found

Learn More

See clinicaltrials.gov

Study Completed

HCRN-LUN17-126

Randomized phase II study of durvalumab or durvalumab plus chemotherapy in Kras mutation positive and PD-L1 high (>/= 50%) NSCLC patients

Shirish Gadgeel

Cancer areas:Lung

No data was found

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-LUN21-530

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)

Cancer areas:Lung

Barbara Ann Karmanos Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Virginia Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-LUN21-534

DURABLE: Delayed or Upfront brain RAdiotherapy in treatment naïve lung cancer patients with asymptomatic or minimally symptomatic Brain metastases and rEarrangements

Cancer areas:Lung

Stanford University

The Ohio State University

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-LUN23-618

Phase II study of adagrasib + stereotactic radiosurgery (SRS) for patients with metastatic KRAS G12C-mutated NSCLC with untreated brain metastases

Cancer areas:Lung

University of Virginia Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-LYM21-544

Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms

Cancer areas:Lymphoma

City of Hope

The Ohio State University

University of Michigan Rogel Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-LYM21-546

A phase II study of pembrolizumab and mogamulizumab in advanced-stage, relapsed/refractory cutaneous T-cell lymphomas

Cancer areas:Lymphoma

University of Michigan Rogel Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-LYM22-565

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Cancer areas:Lymphoma

Barbara Ann Karmanos Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

University of Virginia Cancer Center

UT Southwestern Harold C. Simmons Comprehensive Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

HCRN-MCC20-443

A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (iPRRT Study)

Cancer areas:Merkel Cell Carcinoma

University of Iowa Holden Comprehensive Cancer Center

University of Wisconsin Carbone Cancer Center

Weill Cornell Medicine

Learn More

See clinicaltrials.gov

Currently Enrolling

TBCRC046

A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)

Angela DeMichele

Cancer areas:Breast

Dana-Farber Cancer Institute

Fred Hutchinson Cancer Research Center

Georgetown Lombardi Comprehensive Cancer Center

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Penn Medicine Abramson Cancer Center

The University of Chicago Medicine Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Hope Rugo

Cancer areas:Breast

Dana-Farber Cancer Institute

Duke Cancer Institute

Georgetown Lombardi Comprehensive Cancer Center

Mayo Clinic

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

The University of Chicago Medicine Comprehensive Cancer Center

UC San Francisco

University of Alabama at Birmingham Comprehensive Cancer Center

University of North Carolina Lineberger Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center

Learn More

See clinicaltrials.gov

Enrollment Closed

BTCRC-BRE15-024

A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024

Kari Wisinski

Cancer areas:Breast

University of Illinois Cancer Center

University of Rochester Medical Center - Wilmot Cancer Institute

University of Wisconsin Carbone Cancer Center

Learn More

See clinicaltrials.gov

Study Completed

BTCRC-GI19-400

Prospective assessment of patients with neuroendocrine tumors and current or prior history of carcinoid syndrome or diarrhea undergoing peptide receptor radionuclide therapy with or without telotristat ethyl (NET-PACS Trial) Big Ten Cancer Research Consortium BTCRC-GI19-400

Pashtoon Kasi

Cancer areas:Neuroendocrine Tumors

No data was found

Learn More

See clinicaltrials.gov

Currently Enrolling

BTCRC-GI21-500

A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination with Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI21-500

Cancer areas:Pancreatic

The Ohio State University

Learn More

See clinicaltrials.gov

Currently Enrolling

BTCRC-GI22-564

Phase 2 Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) during First-Line Treatment of Advanced Biliary Tract Cancers: Big Ten Cancer Research Consortium BTCRC-GI22-564

Cancer areas:Cholangiocarcinoma

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

University of Wisconsin Carbone Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

BTCRC-GI22-588

A Phase II Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

Cancer areas:Anal

Rutgers Cancer Institute of New Jersey

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

University of Wisconsin Carbone Cancer Center

Learn More

See clinicaltrials.gov

Currently Enrolling

BTCRC-HEM15-027

Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM15-027

Veronika Bachanova

Cancer areas:Lymphoma

Masonic Cancer Center, University of Minnesota

University of Iowa Holden Comprehensive Cancer Center

University of Wisconsin Carbone Cancer Center

Learn More

See clinicaltrials.gov

Enrollment Closed

BTCRC-HN17-111

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Manish Patel

Cancer areas:Head and Neck

Masonic Cancer Center, University of Minnesota

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

University of Illinois Cancer Center

University of Iowa Holden Comprehensive Cancer Center

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

University of Michigan Rogel Cancer Center

University of Wisconsin Carbone Cancer Center

Learn More

See clinicaltrials.gov

Filter Abstracts

Filter—Publications: Publication Type

Journal Manuscript (0)

Meeting Abstract (0)

Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade

E Miller, T Rose, B Maughan, M Milowsky, M Bilen, B Carthon, X Gao, S Rapisuwon, Q Zhao, M Yu, N Agarwal, M Galsky

Cancer

2024

See Related Study

Read Publication

Journal Article

Phase I/II Trial of Carboplatin, Nab-paclitaxel, and Pembrolizumab for Advanced Non–Small Cell Lung Cancer

R Gentzler, N Mohindra, S Jalal, K Reckamp, R Hall, N Hanna, YK Chae, M Koczywas, I Helenowski, J Patel

The Oncologist

2024

See Related Study

Read Publication

Journal Article

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)

X Le, JD Patel, E Shum, C Baik, RE Sanborn, CA Shu, C Kim, MJ Fidler, R Hall, YY Elamin, J Tu, G Blumenschein, J Zhang, D Gibbons, C Gay, NA Mohindra, Y Chae, Y Boumber, J Sabari, R Santana-Davila, S Rogosin, B Herzberg, B Creelan, B Pellini, T Tanvetyanon, S Heeke, M Hernandez, JE Gray, A Saltos, JV Heymach

Journal of Clinical Oncology

2024

See Related Study

Read Publication

Journal Article

Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT)

M Serzan, O Jegede, R Alter, M Asim Bilen, D Braun, D Einstein, N Haas, H Hammers, D Herchenhorn, J King, K Runcie, J Sosman, C Sternberg, Y Yang, T Choueiri, S Signoretti, MB Atkins

2024

See Related Study

Read Publication

Journal Article

Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC)

J Zaemes, M Hugaboom, V Shah, N Haas, D McDermott, O Jegede, M Bilen, M Stein, J Sosman, R Alter, E Plimack, M Hurwitz, C Wu, D Einstein, H Hammers, S Signoretti, D West, T Denize, M Atkins, D Braun

2024

See Related Study

Read Publication

Journal Article

Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC)

N El Ahmar, S Matar, O Jegede, Y Nabil Laimon, V Savla, A Bagheri Sheshdeh, T Denize, R Assaad Mohanna, TK Choueiri, PJ Catalano, DA Braun, NB Haas, HJ Hammers, M Asim Bilen, MN Stein, JA Sosman, CJ Wu, DF McDermott, MB Atkins, S Signoretti

2024

See Related Study

Read Publication

Journal Article

A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART)

H Mamdani, S Kim, R Gentzler, M Shields, M Furqan, K Pizana, Q Abid, S Ibrahim

2024

See Related Study

Read Publication

Journal Article

Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma

S Rapisuwon, RD Carvajal, G Ansstas, KK Tsai, LF Hernandez-Aya, S Khan, S Chandra, JW Harbour, JA Sosman, A Daud, C Decatur, D Ozisik, M Tan, MB Atkins, SP Patel

2024

See Related Study

Read Publication

Journal Article

A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY)

Y Chen, L Liu, M Pu, S Pena, Q Qin, T Zhang, H Emamekhoo, J Michael Lang, A Patnaik, RR McKay

2024

See Related Study

Read Publication

Journal Article

A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)

RR McKay, L Liu, M Pu, A Araneta, L Wang, N Castano, J Gomez, A Ajmera, H Ye, R Pili, K Runcie, D Joseph McHugh, K Offit, C Judith Paller, NB Haas, J Javier-Desloges, CJ Kane, TM Seibert, A Bagrodia

2024

See Related Study

Read Publication

Journal Article

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

M Galsky, S Daneshmand, S Izadmehr, E Gonzalez-Kozlova, K Chan, S Lewis, B El Achkar, T Dorff, J Paul Cetnar, B Neil, A D’Souza, R Mamtani, C Kyriakopoulos, T Jun, M Gogerly-Moragoda, R Brody, H Xie, K Nie, G Kelly, A Horwitz, Y Kinoshita, E Ellis, Y Nose, G Ioannou, R Cabal, G Kenneth Haines, L Wang, K Mouw, R Samstein, R Mehrazin, N Bhardwaj, M Yu, Q Zhao, S Kim-Schulze, R Sebra, J Zhu, S Gnjatic, J Sfakianos, S K. Pal

Nature Communications

2023

See Related Study

Read Publication

Journal Article

Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

D Doroshow, P O’Donnell, J Hoffman-Censits, S Gupta, U Vaishampayan, E Heath, P Garcia, Q Zhao, M Yu, M Milowsky, M Galsky

JCO Precision Oncology

2023

See Related Study

Read Publication

Journal Article

Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma

A Dudek, M Xi, K Scilla, H Mamdani, B Creelan, A Saltos, T Tanvetyanon, A Chiappori

JTO Clinical Research Reports

2023

See Related Study

Read Publication

Journal Article

The combination of PAC-1 and entrectinib for the treatment of metastatic uveal melanoma

M Boudreau, E Tonogai, C Schane, MX Xi, J Fischer, J Vijayakumar, Y Ji, T Tarasow, T Fan, P Hergenrother, A Dudek

Melanoma Research

2023

See Related Study

Read Publication

Journal Article

Secondary brain metastases prevention after Isolated intracranial progression on trastuzumab/pertuzumab or T-DM1 in patients with advanced human epidermal growth factor receptor 2+ breast cancer with the addition of tucatinib (BRIDGET)

S Sammons, AED Van Swearingen, L Noteware, NA Bagegni, K Moulton, S Threatt, D Jaggers, S Shea, ES Lipp, E Riley, S Jung, G Broadwater, M Ross, K Strickland, S Beyer, A Conlin, A Morikawa, R Murthy, CK Anders

2023

See Related Study

Read Publication

Journal Article

Phase I/II Study of Stereotactic Radiosurgery with Concurrent Olaparib Followed by Adjuvant Durvalumab and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases (SOLARA)

C Shen, Y Abdou, L Chen, X Tan, G Gupta, F Lynce, M Lobbous, E Stringer-Reasor, C Anders

2023

See Related Study

Read Publication

Journal Article

1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell

M Hugaboom, K Street, N Ruthen, L Wirth, OA Jegede, N Schindler, DF McDermott, E Plimack, J Sosman, NB Haas, M Hurwitz, H Hammers, S Signoretti, MB Atkins, CJ Wu, D Braun

2023

See Related Study

Read Publication

Journal Article

LBA71 – A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)

X Le, J Patel, E Shum, J Sabari, C Baik, R Sanborn, K Shu, C Kim, M Jo Fidler, R Hall, N Hanna, J Gray, JV Heymach, A Saltos

2023

Read Publication

Journal Article

Phase II randomized, double-blind, study of mfolfirinox plus ramucirumab versus mfolfirinox plus placebo in advanced pancreatic cancer patients

Walid L. Shaib, Rupji Manali, Yuan Liu, Bassel El-Rayes, Patrick Loehrer, Bert O’Neil, Steven Cohen, Tina Khair, Erwin Robin, Timothy Huyck, Tanios Bekaii-Saab

2023

See Related Study

Read Publication

Journal Article

BRE12-158: A Post-neoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician’s Choice for Patients with Residual Triple-Negative Breast Cancer

BP Schneider, G Jiang, MS, TJ Ballinger, F Shen, C Chitambar, R Nanda, C Falkson, MBBch, FC Lynce , C Gallagher, C Isaacs, M Blaya, E Paplomata, R Walling, K Daily, R Mahtani, MA Thompson, R Graham, ME Cooper, DC Pavlick , LA Albacker, J Gregg, JP Solzak, YH Chen, CL Bales, E Cantor, BA Hancock, N Kassem, P Helft, B O'Neil, AMV Storniolo, S Badve, KD Miller, M Radovich

Journal of Clinical Oncology

2022

See Related Study

Read Publication

Journal Article

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

M Kalra, Y Tong, DR Jones, T Walsh, MA Danso, CX Ma, P Silverman, M King, SS Badve, SM Perkins, KD Miller

NJP Breast Cancer

2021

See Related Study

Read Publication

Journal Article

A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer

CJ Herting, MR Farren, Y Tong, Z Liu, B O’Neil, T Bekaii-Saab, A Noonan, C McQuinn, TA Mace, W Shaib, C Wu, BF El-Rayes, S Shahda, GB Lesinski

Cancer Immunology, Immunotherapy

2021

See Related Study

Read Publication

Journal Article

Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC)

MD Galsky, S Daneshmand, KG Chan, TB Dorff, JP Cetnar, B O'Neil, A D'souza, R Mamtani, C Kyriakopoulos, P Garcia, S Izadmehr, M Yu, Q Zhao, R Mehrazin, SC Lewis, J Sfakianos, SK Pal

2021

See Related Study

Read Publication

Journal Article

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer ABATE study

D Kilari, A Szabo, KA Bylow, RS Alter, AA Nelson, E Lemke, WA Hall, S Johnson, P Langenstroer, K Jacobsohn, NB Davis, C Fung, MI Milowsky

2021

See Related Study

Read Publication

Journal Article

Urothelial cancer-GENOmic analysis to improve patient outcomes and research (UC-GENOME): a bladder cancer advocacy network (BCAN) led collaborative research study

JS Damrauer, J Klomp, W Beck, M Zhou, E Plimack, M Galsky, P Grivas, N Hahn, P O’Donnell, G Iyer, DI Quinn, KA Hoadley, WY Kim, MI Milowsky

2021

See Related Study

Read Publication

Journal Article

Randomized phase II trial of pembrolizumab/carboplatin vs. carboplatin alone for breast cancer with chest wall recurrence: TBCRC044

N Vidula, R Nanda, K Miller, L Emens, V Abramson, B Park, MC Liu, A Goga, H Rugo

2021

See Related Study

Journal Article

Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma

MS Lee, J Chao, MF Mulcahy, PM Kasi, AT Alistar, S Mukherjee, M Akce, DT Moore, CA Carlson, AJ McRee

2021

See Related Study

Read Publication

Journal Article

A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC)

AR He, AY Kim, BM Toskich, K Mody, K Kim, S Stein, L Goyal, TA Abrams, D Brown, LW Goff, RD Kim, N Parikh, T Sandow, D Johnson, RV Iyer, M Petroziello, SS Krishnamurthi, C Martin, Y Jiang, N Akhter

2021

See Related Study

Read Publication

Journal Article

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC)

MB Atkins, O Jegede, NB Haas, DF McDermott, MA Bilen, J Hawley, JA Sosman, RS Alter, ER Plimack, MC Ornstein, ME Hurwitz, DJ Peace, S Signoretti, CJ Wu, PJ Catalano, HJ Hammers

2021

See Related Study

Read Publication

Journal Article

Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients

WL Shaib, M Rupji, TA Khair, EL Robin, BF El-Rayes, TK Huyck, Y Liu, MB Sonbol, TS Bekaii-Saab

2021

See Related Study

Read Publication

Journal Article

Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

MD Galsky, A Mortazavi, MI Milowsky, S George, S Gupta, MT Fleming, LH Dang, DM Geynisman, R Walling, RS Alter, M Kassar, J Wang, S Gupta, N Davis, J Picus, G Philips, DI Quinn, GK Haines III, NM Hahn, Q Zhao, M Yu, SK Pal

Journal of Clinical Oncology

2020

See Related Study

Read Publication

Journal Article

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial

M Radovich, G Jiang, BA Hancock, C Chitambar, R Nanda, C Falkson, FC Lynce, C Gallagher, C Isaacs, M Blaya, E Paplomata, R Walling, K Daily, R Mahtani, MA Thompson, R Graham, ME Cooper, DC Pavlick, LA Albacker, J Gregg, JP Solzak, Y Chen, CL Bales, E Cantor, F Shen, AMV Storniolo, S Badve, TJ Ballinger, C Chang, Y Zhong, C Savran, KD Miller, BP Schneider

JAMA Oncology

2020

See Related Study

Read Publication

Journal Article

A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer

GA Durm, SK Jabbour, SK Althouse, Z Liu, AA Sadiq, RT Zon, SI Jalal, GH Kloecker, MJ Williamson, KL Reckamp, RM Langdon, EA Kio, RD Gentzler, BA Adesunloye, WA Harb, RV Walling, ML Titzer, NH Hanna

Cancer

2020

See Related Study

Read Publication

Journal Article

Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study

B Anouti, S Althouse, G Durm, N Hanna

Clinical Lung Cancer

2020

See Related Study

Read Publication

Journal Article

A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE)

M Milowsky, N Davis, C Fung, S Johnson, P Langenstroer, K Jacobsohn, K Bylow, D Kilari

2020

See Related Study

Read Publication

Journal Article

Phase 1 trial of durvalumab in combination with BCG or external beam radiation in BCG-unresponsive non-muscle invasive bladder cancer patients

NM Hahn, MA O’Donnell, JA Efstathiou, M Zahurak, G Rosner, J Smith, MR Kates, TJ Bivalacqua, PT Tran, DY Song, AS Baras, A Matoso, W Choi, KN Smith, DM Pardoll, L Marchionni, B McGuire, B Johnson, T O’Neal, DJ McConkey, TL Rose, M Bjurlin, EA Lim, CG Drake, CB Anderson, DL Lamm, DM Geynisman, MA Hallman, EM Horwitz, E Al-Saleem, DYT Chen, A Kutikov, G Guo, TA Masterson, N Adra, HZ Kaimakliotis

2020

See Related Study

Read Publication

Journal Article

A phase II trial of atezolizumab (atezo) and bevacizumab (bev) in cisplatin-ineligible patients (pts) with advanced/unresectable urothelial cancer (UC)

AV Balar, SA Funt, S Gupta, AZ Dudek, AR Boiles, DA Vaena, D Kilari, JE Rosenberg

2020

See Related Study

Read Publication

Journal Article

Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188

CJ Hoimes, N Adra, MT Fleming, HZ Kaimakliotis, J Picus, ZL Smith, R Walling, EJ Trabulsi, JH Hoffman-Censits, MO Koch, C Cary, R Abouassaly, C Eitman, P Fu, G Goolamier, AC Calaway, LE Ponsky, WK Kelly

2020

See Related Study

Read Publication

Journal Article

Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)-ineligible cohort of HCRN GU14-188

HZ Kaimakliotis, N Adra, WK Kelly, EJ Trabulsi, RC Lauer, J Picus, ZL Smith, R Walling, TA Masterson, AC Calaway, MO Koch, E Sonderman, P Fu, G Goolamier, C Eitman, LE Ponsky, CJ Hoimes

2020

See Related Study

Read Publication

Journal Article

Phase II trial of atezolizumab plus chemotherapy after progression on single-agent PD-1 or PD-L1 inhibitor in cisplatin ineligible patients with advanced urothelial carcinoma

N Adra, RJ Hauke, HZ Kaimakliotis, S Gulati, N Hashemi, R Pili

2020

See Related Study

Read Publication

Journal Article

Circulating TP53 mutations in TNBC after neoadjuvant chemotherapy is associated with rapid disease recurrence: Correlative analysis from clinical trial BRE12-158

M Radovich, N Kassem, G Jiang, BA Hancock, BP Schneider

2020

See Related Study

Read Publication

Journal Article

A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination (HR) defective or loss of heterozygosity (LOH) high-metastatic esophageal/GEJ/proximal gastric adenocarcinoma

H Mamdani, R Mehta, C Fountzilas, M Radovich, S Perkins, SI Jalal

2020

See Related Study

Read Publication

Journal Article

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC)

MB Atkins, O Jegede, NB Haas, DF McDermott, MA Bilen, CG Drake, JA Sosman, RS Alter, ER Plimack, BI Rini, ME Hurwitz, DJ Peace, S Signoretti, CJ Wu, PJ Catalano, HJ Hammers

2020

See Related Study

Read Publication

Journal Article

The association between immune-related adverse events and efficacy outcomes with consolidation pembrolizumab after chemoradiation in patients with stage III NSCLC

N Shukla, SK Althouse, AA Sadiq, SI Jalal, SK Jabbour, R Zon, GH Kloecker, WB Fisher, KL Reckamp, EA Kio, RM Langdon, B Adesunloye, RD Gentzler, NH Hanna, GA Durm

2020

See Related Study

Read Publication

Journal Article

RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC

A Saltos, C Baik, RE Sanborn, E Shum, C Kim, R Hall, MJ Fidler, CA Shu, G Otterson, J Patel, KK Wong, N Hanna, J Gray, J Heymach, X Le

2020

See Related Study

Read Publication

Journal Article

Phase II randomized, double-blind, study of mfolfirinox plus ramucirumab versus mfolfirinox plus placebo in advanced pancreatic cancer patients

WL Shaib, B O'Neil, BF El-Rayes, SJ Cohen, TA Khair, EL Robin, TK Huyck, RA Redman, AR Sama, M Kassar, TS Bekaii-Saab

2019

See Related Study

Read Publication

Journal Article

Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC)

MD Galsky, SK Pal, A Mortazavi, MI Milowsky, S George, S Gupta, MT Fleming, LH Dang, DM Geynisman, R Walling, RS Alter, EL Robin, J Wang, S Gupta, DD Chism, J Picus, G Philips, DI Quinn, NM Hahn, M Yu

2019

See Related Study

Read Publication

Journal Article

Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158

M Radovich, G Jiang, C Chitambar, R Nanda, C Falkson, FC Lynce, C Gallagher, C Isaacs, M Blaya, E Paplomata, R Walling, K Daily, R Mahtani, MA Thompson, R Graham, ME Cooper, DC Pavlick, L Albacker, J Gregg, CL Bales, BA. Hancock, E Cantor, F Shen, AMV Storniolo, S Badve, T Ballinger, KD Miller, BP Schneider

2019

See Related Study

Read Publication

Journal Article

Ph I/II Carboplatin, Nab-Paclitaxel and Pembrolizumab for Advanced NSCLC

R Gentzler, N Mohindra, S Jalal, K Reckamp, R Hall, N. Hanna, YK Chae, V Villaflor, M Koczywas, I Helenowski, A Rademaker, J Patel

2019

See Related Study

Read Publication

Journal Article

P1.18-05 ChemoXRT w/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy

G Durm, S Althouse, A Sadiq, S Jalal, S Jabbour, R Zon, G Kloecker, M Williamson, K Reckamp, E Kio, R Langdon, B Adesunloye, R Gentzler, W Harb, R Walling, C Yeon, M Koczywas, N Hanna

2019

See Related Study

Read Publication